Shots:
- Janssen to present new data from the fixed-duration cohort of P-II CAPTIVATE study, demonstrating 95% of patients treated with combined Imbruvica + Venetoclax were alive and progression-free @2yrs. with deep remissions were seen across all subgroups, including patients with high-risk CLL
- Additionally, Janssen will present 7yrs. data from the RESONATE-2 study on PFS and OS benefits with single-agent Imbruvica, reinforcing the survival benefits and long-term tolerability of therapy for patients with CLL
- The results of RESONATE-2 study supporting the long-term benefits of Imbruvica monothx. in 1L CLL, supporting the use of Imbruvica as SOC
Click here to read full press release/ article | Ref: Janssen | Image: Ars Technica
The post Janssen to Present Results of Imbruvica (ibrutinib)-based Combination Regimen as 1L Treatment for Chronic Lymphocytic Leukemia at ASCO first appeared on PharmaShots.
